Medical and Economic Evaluation for Intermediate-risk Prostate Cancer

Exclusion Criteria

• •PSA level \> 20;
• •Gleason \> 7;
• •clinical T3A or T3B or MRI (a simple suspicion/ doubt on the MRI regarding the T3A won't be an exclusion criterion);
• •prostate volume \> 60 cc;
• •pelvic lymph nodes involvement at dissection or imaging (ADP \> 1.5 cm);
• •concurrent hormone therapy;
• •the presence of distant metastasis (M1);
• •history of abdominal or pelvic irradiation;
• •history of prostate resection in the previous 6 months and/or not allowing the implantation of markers;
• •history of uncontrolled cancer and/or treated since less than 5 years (excepting the basal-cell carcinoma);
• •urinary discomfort with an IPSS (International Prostate Symptom Score) \> 15 (without alpha-blocking);
• •inflammatory bowel disorder such as ulcerative colitis or the Crohn's disease;
• •other undergoing study that may interfere with the present study;
• •patient under legal protection measure.